Which laboratory tests should be monitored in patients receiving IV heparin?

The correct answer includes monitoring hemoglobin (HGB), hematocrit (HCT), and platelets in patients receiving IV heparin due to the potential effects of heparin therapy on blood components.

Specifically, patients on heparin are at risk for heparin-induced thrombocytopenia (HIT), a serious condition that can lead to a decrease in platelet levels. Regular monitoring of platelets helps detect any significant drop early, allowing for timely intervention. Additionally, monitoring hemoglobin and hematocrit is important to assess for possible bleeding complications, as heparin can increase the risk of hemorrhage.

While activated partial thromboplastin time (APTT) is a critical parameter for adjusting heparin dosage, it is not the only consideration when managing a patient on this anticoagulant. The broad monitoring of blood components, including hemoglobin, hematocrit, and platelet levels, ensures a more comprehensive assessment of the patient's safety and treatment efficacy. This monitoring helps to balance the risks of clotting versus bleeding associated with heparin therapy.